logo
Share SHARE
FONT-SIZE Plus   Neg

Shire's DERMAGRAFT Approved In Canada For Treating Diabetic Foot Ulcers

Shire Plc (SHP.L, SHPG) said its lead regenerative medicine product, DERMAGRAFT (human fibroblast-derived dermal substitute) secured regulatory approval from Health Canada as a class IV medical device for the treatment of diabetic foot ulcers (DFUs), a complication of diabetes.

Shire Regenerative Medicine plans to make DERMAGRAFT available in Canada in the first quarter of 2013, and will leverage Shire's current infrastructure and commercial knowledge of the Canadian healthcare system.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Women's specialty-clothing retailer J. Jill Inc. said it has launched an initial public offering of 11.67 million shares of its common stock. All shares are being sold by an existing stockholder and J. Jill will not receive any proceeds from the offering. Long queues at peak dining hours at Wendy's may be a history, as the company is planning to introduce automated self ordering kiosks at its more than 1000 retail locations by this year end. The automation will also help in cutting labor costs. Canadian music retail chain Sunrise Records said it plans to take over 70 retail spaces in Canada being vacated by HMV Canada, the industry's largest retailer. The new brick and mortar locations are in malls across Canada. However, Sunrise's expansion comes as people are increasingly shifting to streaming options for music and videos rather than buying tangible, touchable albums.
comments powered by Disqus
Follow RTT